Loading
A phase 2 trial of Dacarbazine, Temozolomide, Paclitaxel / nab-paclitaxel in melanoma, run by Suzhou BlueHorse Therapeutics Co., Ltd., now recruiting.
A Phase II Trial of LM103 in Advanced Melanoma is a phase 2 interventional study registered as NCT07310784 by Suzhou BlueHorse Therapeutics Co., Ltd., with 92 participants planned, started 2025-12-16 and due to reach its primary completion in 2027-12-31. Interventions recorded: LM103 TILs Injection, Dacarbazine, temozolomide, paclitaxel, carboplatin/cisplatin. Conditions listed: Advanced Melanoma. No results are recorded here; the registry entry is the source.
Shares Dacarbazine, Temozolomide, Advanced melanoma (unresectable stage III and stage IV), Paclitaxel / nab-paclitaxel.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Temozolomide, Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Temozolomide, Cisplatin.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Temozolomide, Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma.